516 patents
Page 9 of 26
Utility
Heterocyclic compounds as LSD1 inhibitors
2 Aug 22
Chunhong He, Zhenwu Li, Liangxing Wu, Wenqing Yao, Fenglei Zhang
Filed: 28 Aug 20
Utility
Pyrido[3,2-d]pyrimidine compounds as immunomodulators
2 Aug 22
Jingwei Li, Liangxing Wu, Wenqing Yao
Filed: 29 Sep 20
Utility
Pyrimidinones as PI3K inhibitors
2 Aug 22
The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
Filed: 30 Sep 20
Utility
Combination Therapy Comprising A2A/A2B Inhibitors, PD-1/PD-L1 Inhibitors, and ANTI-CD73 Antibodies
28 Jul 22
Disclosed are combination therapies comprising administration of a CD73 inhibitor, an adenosine A2A or A2B receptor inhibitor, and a PD-1/PD-L1 inhibitor.
Hui Wang, Juan Carlos Almagro, Rebecca A. Buonpane, Peter Niels Carlsen, Taisheng Huang, Yong Li, Horacio G. Nastri, Chao Qi, Shaun M. Stewart, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Jing Zhou, Wenyu Zhu
Filed: 29 Dec 21
Utility
Substituted heterocyclic derivatives as PI3K inhibitors
26 Jul 22
Stacey Shepard, Andrew P. Combs
Filed: 12 Nov 19
Utility
Combination Therapy Comprising Jak Pathway Inhibitor and Rock Inhibitor
21 Jul 22
The present application provides combination therapies comprising a JAK inhibitor and a ROCK inhibitor, and methods of using the same to treat disorders such as graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), and systemic sclerosis (scleroderma).
Michael Peel, Paul Smith
Filed: 10 Jan 22
Utility
Pyridine and Pyridimine Compounds As PI3K-GAMMA Inhibitors
21 Jul 22
Richard B. Sparks, Stacey Shepard, Andrew P. Combs, Andrew W. Buesking, Lixin Shao, Haisheng Wang, Nikoo Falahatpisheh
Filed: 25 Mar 22
Utility
Pyrazolopyridine Compounds and Uses Thereof
21 Jul 22
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Hai Fen Ye, Qinda Ye, Wenqing Yao
Filed: 22 Dec 21
Utility
Salts of Tam Inhibitors
21 Jul 22
The present application provides salt forms of N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as processes and intermediates related thereto.
Zhongjiang Jia, Yongzhong Wu, Yongchun Pan, Jiacheng Zhou, Qun Li
Filed: 13 Aug 21
Utility
Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
19 Jul 22
Taisheng Huang, Xiaozhao Wang
Filed: 28 Jan 20
Utility
Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
12 Jul 22
Alexander Sokolsky, Sarah Winterton, Liangxing Wu, Wenqing Yao
Filed: 14 Feb 20
Utility
Crystalline solid forms of a BET inhibitor
5 Jul 22
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
Filed: 18 Dec 20
Utility
Jak Inhibitor with a Vitamin D Analog for Treatment of Skin Diseases
30 Jun 22
The present disclosure relates to topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization, using (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.
Paul SMITH, Zheng ZHANG, Melissa PARKER
Filed: 3 Dec 21
Utility
Oral Formulation for a PD-L1 Inhibitor
23 Jun 22
Disclosed are oral formulations for a compound which modulates PD-1/PD-L1 protein/protein interaction, or a pharmaceutically acceptable salt thereof, which do not require cold chain storage.
Yonglai Yang, Trupti Sheth, Xinsheng Xie
Filed: 17 Dec 21
Utility
Heterocyclic Compounds As Immunomodulators
23 Jun 22
Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
Filed: 15 Feb 22
Utility
ANTI-CD19 Combination Therapy
16 Jun 22
The present disclosure is directed to a therapeutic combination of an anti-CD19 antibody and R-CHOP or an anti-CD19 antibody, lenalidomide, and R-CHOP for use in the treatment of diffuse large B cell lymphoma.
Günter FINGERLE-ROWSON, Wolfram BRUGGER, Oliver MANZKE, Francis SEGUY
Filed: 3 Dec 21
Utility
Bicyclic Heteroarylaminoalkyl Phenyl Derivatives As PI3K Inhibitors
9 Jun 22
Yun-Long Li, Andrew P. Combs
Filed: 24 Aug 21
Utility
JAK1 Pathway Inhibitors for the Treatment of Vitiligo
9 Jun 22
This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.
Paul Smith, Kurt Andrew Brown, Michael D. Howell, Fiona Kuo, James Lee, Leandro Luiz Dos Santos, Beth Rumberger
Filed: 8 Dec 21
Utility
Pyridine and pyridimine compounds as PI3K-gamma inhibitors
7 Jun 22
Richard B. Sparks, Stacey Shepard, Andrew P. Combs, Andrew W. Buesking, Lixin Shao, Haisheng Wang, Nikoo Falahatpisheh
Filed: 29 Mar 19
Utility
Tricyclic Urea Compounds As JAK2 V617F Inhibitors
2 Jun 22
The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
Yanran Ai, Onur Atasoylu, Yu Bai, Joseph Barbosa, David M. Burns, Daniel Levy, Brent Douty, Hao Feng, Leah C. Konkol, Cheng-Tsung Lai, Xun Liu, Song Mei, Jun Pan, Haisheng Wang, Liangxing Wu, Wenqing Yao, Eddy W. Yue
Filed: 1 Jul 21